FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

Medicine, Hematology, Oncology +17

Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

Brunangelo Falini, Cristina Mecucci, Enrico Tiacci et al. · New England Journal of Medicine · 2005 · 1.9K citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +14

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

Medicine, Genetics, Hematology +14

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

Richard F. Schlenk, Konstanze Döhner, Jürgen Krauter et al. · New England Journal of Medicine · 2008 · 1.6K citations

Life Sciences, Genetics, Molecular Genetics +17

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew et al. · Blood · 2001 · 1.5K citations · Full text

Life Sciences, Genetics, Hematology +16